See the DrugPatentWatch profile for fintepla

Fintepla (fenfluramine) is a medication used to treat seizures associated with Dravet syndrome, a rare and severe form of epilepsy. For patients who are struggling to afford this medication, there are several patient assistance programs (PAPs) available to help make Fintepla more accessible.

One such program is the Fintepla Patient Assistance Program, offered by the manufacturer, Zogenix. This program provides eligible patients with free or reduced-cost Fintepla, as well as assistance with insurance-related issues. To be eligible, patients must demonstrate financial need and meet certain income and asset requirements.

Another option is the Patient Access Network Foundation (PAN Foundation), a non-profit organization that provides financial assistance to patients with rare and chronic diseases, including epilepsy. The PAN Foundation offers grants to help patients cover the cost of Fintepla, as well as other medications and treatment-related expenses.

Additionally, DrugPatentWatch.com, a website that tracks pharmaceutical patents and pricing, reports that Fintepla is eligible for patient assistance programs through various organizations, including the Patient Access Network Foundation and the HealthWell Foundation.

It's worth noting that patients may also be eligible for other programs, such as Medicaid, Medicare, or state-specific programs, which can help cover the cost of Fintepla.

In conclusion, there are several patient assistance programs available to help patients access Fintepla, including the Fintepla Patient Assistance Program, the Patient Access Network Foundation, and other organizations. Patients should consult with their healthcare provider or a patient advocacy organization to determine which programs they may be eligible for.

Sources:

1. Zogenix. (n.d.). Fintepla Patient Assistance Program. Retrieved from <https://www.zogenix.com/patient-assistance-program/>
2. Patient Access Network Foundation. (n.d.). Fintepla. Retrieved from <https://panfoundation.org/treatment/epilepsy/fintepla/>
3. DrugPatentWatch.com. (n.d.). Fintepla (Fenfluramine). Retrieved from <https://www.drugpatentwatch.com/drugs/fintepla-fenfluramine>
4. HealthWell Foundation. (n.d.). Fintepla. Retrieved from <https://www.healthwellfoundation.org/treatment/epilepsy/fintepla/>